POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...
POTOMAC, MD / ACCESS Newswire / May 22, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its ...
IGC Pharma (IGC) announced that its ongoing Phase 2 trial for agitation in Alzheimer’s disease has been officially named CALMA. The trial’s new identity reflects its mission to address agitation, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results